Recurrent hepatitis B in liver allograft recipients by Demetris, JA et al.
-------------
_~d 
Recurrent Hepatitis B in Liver Allograft Recipients 
Differentiation Between Viral Hepatitis B and Rejection 
A. JAKE DEMETRIS, MD, R. JAFFE, MBBCh, 
D. G. SHEAHAN, MB, MSc, 
J. BURNHAM, BA HT(ASCP), J. SPERO, MD, 
S. rwATSUKI, MD, D. H. VAN THEIL, MD, 
and T. E. STARZL, MD, PhD 
The histologic findings in the original liver obtained from 
9 liver allograft patients with active B virus hepatitis were 
compared with 28 posttransplant pathology specimens. 
All specimens were studied with the use of light and im-
munohistochemical microscopy in conjuction with per-
tinent clinical data. Eight of tbe 9 patients bad chronic 
active hepatitis B (HB) with cirrhosis, prior to transplant, 
one of which had coexistent hepatocellular carcinoma. 
The ninth patient had fulminant hepatic necrosis second-
ary to acute HB prior to transplantation. In all of the pa-
tients with chronic HB prior to transplantation who sur-
vived more than 2 months after transplantation recurrent 
infection of the graft developed despite perioperative HB 
HEPATIC allografts are susceptible to a wide variety 
of insults, which can produce considerable differential 
diagnositic difficulties for the surgical pathologist re-
sponsible for interpreting biopsy specimens obtained 
from such patients. One such problem is the separa-
tion of viral hepatitis from allograft rejection.1.2 This 
potential complication is encountered most commonly 
1-2 months or more after transplantation. 1 Some viral 
infections of the transplanted liver such as cytomegalo-
virus (CMV) and herpes simplex virus (HSV) can be 
identified by their characteristic pathologic changes 
and/or immunoenzyme staining of the tissue specimen 
for viral antigens. 1.3.4 On the basis of histopathologic 
observations alone, however, other viral hepatidites such 
as hepatitis A. B, and non-A non-B cannot be specifi-
cally diagnosed, although subtle histologic differences 
between these various types of hepatitis have been re-
ported.5 However, with the combined use of immuno-
peroxidase stains and serologic studies for specific vi-
ral antigens, hepatitis B (HB) can be identified as the 
agent responsible for the hepatic injury seen in some 
of these cases. 
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immunoglobulin therapy. The patient with acute fulmi-
nant hepatitis B pretransplant has done well postopera-
tively and has evidence ofHB virus immunity (positive 
anti-HBs) 15 months after transplantation. Examination 
of tissue specimens obtained during episodes of allograft 
dysfunction in these 9 patients indicate that pathologic 
alterations of active HB infection of the allograft are as-
sociated with a preferential lobular insult, whereas those 
occurring in rejection preferentially involve portal tract 
structures. Serologic data combined with biopsy histo- / 
pathologic data are essential in distinguishing between 
the two quite different events. (Am J Pathol 1986, 125: 
161-172) 
It has been reported that B-virus carriers can develop 
recurrence of their original diseaseu after liver trans-
plantation. In one particularly well-studied case, the 
clinical evolution, serologic changes and histopatho-
logic alterations caused by recurrent disease under in-
fluence of chronic immunosuppression were described.6 
The present report is based on examination of the path-
ologic specimens obtained from an additional 9 liver 
transplant patients who were positive for hepatitis B 
surface antigen (HBsAg) by serologic testing at the time 
of transplantation. The purpose of the study was to 1) 
document the course of hepatitis B virus (HBV) infec-
tion in this unique group of patients during the post-
transplant period and 2) attempt to identify character-
istic histopathologic changes in posttransplant 
specimens of help in the separation of viral hepatitis, 
particularly type B, from allograft rejection. 
Accepted for publication May 27, 1986. 
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Materials and Methods 
Patient Selection 
Patients were selected for inclusion in this study on the 
basis of pre-transplant hepatitis serology which was pos-
itive for HBsAg. For all patients there was at least one 
posttransplant pathologic specimen available for review. 
These specimens included 22 biopsies, 3 failed allo-
grafts, and 3 autopsy specimens. 
Histopathology 
Tissue specimens were fixed in acid or neutral buffered 
formalin, embedded in paraffin, and routinely stained 
with hematoxylin and eosin (H&E), trichrome, and re-
ticulin. The slides were reviewed retrospectively (Cases 
1-6) and prospectively (Cases 7-9). Pathologic speci-
mens are identified in the text according to the follow-
ing designations: FG, failed allograft; AU, autopsy; LB 
8.220A, liver biopsy from Patient 8, 220 days after 
transplant, (A) from the first graft. Final analysis 
of each case incorporated the clinical course, HB sero-
logic studies, and immunoperoxidase staining for HB 
viral antigens. 
Immunoperoxidase Staining for HBsAg and HBcAg 
Surgical and autopsy specimens used for these studies 
were fixed as above and sectioned at four microns. 
AJP , 0<.000 1 CJe6 
;', •... ,
-. 
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Sections were stained for hepatitis surface antigen ,_ 
utilizing the avidin-biotin-peroxidase complex method ' .• 
of Hsu. S Goat antiserum specific for HBsAg (Dako 
Corporation, Santa Barbara, Calif) in a dilution of 
I :1200 produced optimal staining. All procedures 
were carried out at room temperature. A O.05It!o DAB 
(3',3'-diaminobenzidine) solution produced a dark 
brown color in positive-staining cells. 
Tissue sections were stained for hepatitis B core an-
tigen (HBcAg) by Sternberger's9 PAP technique (peri-
oxidase-antiperoxidase). The hepatitis B core antise-
rum produced in rabbits was supplied by the Dako 
Corporation. The chromogen 3-amino-9-ethylcarbazole 
produced a bright brick-red color in positive staining 
nuclei of hepatocytes. Nonimmune serum substituted 
for the primary antibody, served as the negative con-
trol for each staining procedure and yielded no stain-
ing. Liver tissue from known seropositive cases of HB 
were used as the biologic positive-staining controls. 
Clinicopathologic Correlation 
The results of liver injury tests, HB serologic studies, 
and the details of immunosuppressive therapy for re-
jection, immunoprophylaxis for HBV, and clinical im-
pressions were obtained from the patient chart andlor 
through personal communication with the attending 
physicians and surgeons. 
Table 1-Demographic Data, Treatment Regimens, Duration of Disease, and HLA Typing 
Patient 
1 2 3 4 5 6 7 8 9 
R.H. J.S. PW.C. M.V.D. J.L DA A.C. D.T. A.C. 
Age/sex 281M 45/1.1 271M 341M 281M 231M SliM 341M 381M 
Pretransplant CirrhosiS Cirrhosis Cirrhosis Cirrhosis Fulminant Cirrhosis 
disease' CAH·B CAH-8 CAH-B CAH·B Acute Cirrhosis CAH-8 CirrhosiS Cirrhosis 
Alcohol Hepatitis B CAH-8 Hepatoma CAH-B CAH-B 
abuse 
Pretransplant None Azathioprine Steroids Steroids None Steroids ? None None 
treatment Steroids 
Duration of 4 years 6-7 years 8 years >10 years <3 weeks >4 years >5 years ? 14 years 
HB infection 
HLA type 
Donor Al Al.24(9) NOt NO Al,2 A2.31* NO A28.3Ot A 2,24 
B49(21) B14,BW44 (12) B60.BW6 B15, 151 B57-BW4 B7,52.BW4,6 
DR;NA DR; 4. 7 DRS.6 DR 2.5 DR 2.8 DR 2.6 
Recipient Al.2 At.ll A26 (10) A2,24 A25(16) A34.36 A24.26 A28- A2.24 
B17,22 88.14 B51(5).53 840, BW6 A32(18) B35 835 Bl3-BW4 B38,27.BW4 
DR 2.7 DR 6y DR 3.5 DR4 B8 B14 DR 5,7 DR 5,7 DR 6.7 DR 1,2 
DR 1.3 
• CAH-B, chronic-active hepatitis. 
t NO. not done. 
* First donor. 
9 
A.C. 
8/M 
irrhosis 
AH·B 
one 
I years 
2.24 
7.52.BW4.6 
A 2.6 
2.24 
38.27.BW4 
A 1.2 
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ble 2 - Primary Disease Pathology and Immunotherapy for HBV 
i8 .. _-.-
Immunoperoxidase staining pattern· 
p~tl~~~ __ --~mary- disease HBs Ag 
1 R.H. Cirrhosis - active HCt cytoplasm in 
10% cells in 
isolated nodules 
2 JS Cirrhosis - active Negative 
3 pWC. Cirrhosis - active HC cytoplasm in 
30% cells in 
isolated nodules 
4MVD Cirrhosis - active HC cytoplasm in 
10% cells in 
isolated nodules 
5 J.L. Massive necrosis Difficult to 
interpret because 
of necrosis 
6 D.A. Cirrhosis-active HC cytoplasm in 
occasional para-
septal cell 
7 A.C. Cirrhosis. hepato- HC cytoplasm in 
cellular carcinoma 300,1, cells distrib-
uted randomly 
8 D.T Cirrhosis - active HC cytoplasm in 
10% cells in 
isolated nodules 
9 A.C. Cirrhosis-active HC cytoplasm in 
<10% cells dis-
tributed randomly 
• No staining of biliary epithelium seen for HBs Ag or HBc Ag in any case. 
t HBIG. B immune globulin. 1M. intramuscular. IV. intravenously. 
t HC. hepatocellular. 
Results 
Patient Population and Pretransplant Disease 
The patient demographic data, pretransplant treat-
ment regimens, duration of disease, and HLA typing 
of both donor and recipient are shown in Table 1. The 
primary disease histopathology with immunoperoxi-
dase staining for HB antigens are shown in Table 2. 
Immunotherapy for UB 
Eight of the 9 patients were treated with various doses 
of hepatitis B immunoglobulin (HBIG) in the peritrans-
plant period. Details of the treatment regimen are shown 
in Table 2. 
Posltransplant Analysis of Graft Dysfunction 
Episodes of graft dysfunction occurred in all 9 pa-
tients after transplantation and were identified by ele-
vated serum levels of liver enzymes and clinical symp-
toms. Biopsy specimens were obtained at the onset of 
HBc Ag HBIGt therapy (total dose) 
Negative 5 ml 1M 1 day post~ 
(5 mil 
Positive in occasional 5 ml 1M on 121h and 38th day 
paraseptal HC nucleus post-op (10 mil 
Negative 20 ml 1M intraoperatively. 
immediately post-op. 1 month 
and 6 months post-op (80 mil 
Negative 5 ml 1M intraoperatively 
and immediately post-op (10 mil 
Difficult to 100 ml IV intraoperatively 
interpret because during an hepatic state. immed· 
of necrosis iately and 1 week post-op 
(300 mil 
Negative 100 ml IV intraoperatively 
and immediately post-op 
(200 mil 
Positive in None 
occasional HC 
nucleus 
Negative 100 ml IV intraoperatively 
during anhepatic state, after 
perfusion and immediately post·up 
(300 mil 
Negative 100 ml IV intraoperatively during 
anhepatic state. after perfusion 
and immediately post-op (300 mil 
graft dysfunction in all 9 patients (see Table 3), and fol-
low-up biopsies or failed grafts were obtained in most. 
Episodes of graft dysfunction attributed to acute cel-
lular rejection (LBs 3.14, 3.62,4.42,4.78,5.40, and 5.50; 
FG 6.11, and LBs 8.7 A and 8.26A) all occurred initially 
within the first 2 months after transplant (range, 11-42 
days). Clinically, dysfunction was accompanied by leth-
argy, graft tenderness, and liver biochemical abnormal-
ities. Histologically, all the specimens had pathologic 
alterations which were primarily based in the portal 
tracts. The morphologic manifestations of acute cellu-
lar rejection consisted of a portal expansion secondary 
to predominantly mononuclear but mixed inflamma-
tory infiltrate consisting of large and small lymphocytes, 
plasma cells, macrophages, eosinophils, and neu-
trophils. The portal inflammatory cells were seen 
around, beneath, and within the portal venular endo-
thelium and the bilary ductular epithelium. The endo-
thelial and biliary epithelial cells showed nuclear en-
largement and evidence of damage such as paranuclear 
vacuolation and cytoplasmic eosinophilia. The endothe-
lial cells were at times lifted from the underlying con-
nective tissue, and occasional disruption of the lumi-
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Figure lA-Patient 5. LB 5.50 showing a prominent portallract infillrate with portal edema and a relative lack of lobular changes. (H&E. x125) 8-
Higher.power magnification of the above section showing inflammatory cell infiltration and damage of bile ductules (8/TOWS) and venous endothelium (arrow-
head). (H&E. x 315) 
nal integrity of the bile ductules was present. The limit-
ing plate was generally intact, but occasionaly "spilI-over" 
of the infiltrate into the periphery of the lobule asso-
ciated with periportal hepatocyte necrosis was seen. 
Lobular changes were generally minimal and consisted 
of centrilobular cholestasis and occasional central vein 
changes similar to those described in the portal veins. 
A representative example of the changes seen with acute 
cellular rejection is shown in Figure 1. Stains for HB 
antigens were negative in these specimens except for 
faint staining for HBsAg seen in the plasma within the 
blood vessels. All of the episodes diagnosed as acute 
cellular rejection had a partial or complete response to 
antirejection therapy, as evidenced by improvement in 
liver enzyme levels. 
Episodes of graft dysfunction attributed to recurrent 
HB (LB 1.125, 2.295, AU 2.450,3.246, 7.105, 8.220A, 
8.898, 9.195, and 9.223) all initially occurred more than 
8 weeks after transplant (range, 89-295 days) (Table 3). 
Clinically, dysfunction was accompanied by malaise, 
nausea, jaundice, and elevated liver enzymes (most fre-
quently ALT and AST). Histologically, all the speci-
mens in which dysfunction was due to HB had in com-
mon the presence of pathologic lobular alterations ~ith 
minimal evidence of inflammatory cell damage to por-
tal venular endothelium or biliary epithelium. Lobular 
morphologic alterations in LB 1.125, 2.295, 3.246, 
8.220A, and 8.89B consisted of prominent disarray, in-
flammation, ballooning, and random hepatocellular 
acidophilic necrosis. A moderate degree of portal in-
flammation was present in LB 1.125, 2.295, and 3.246, 
along with focal biliary epithelial cell vacuolation and 
stratification. However, disruption of the luminal integ-
rity of the ductules was not seen. Also, the portal tract 
changes were much less prominent than those seen dur-
ing episodes of acute cellular rejection. Piecemeal necro-
sis was also observed in these specimens. Lobular altera-
tions in LB 7.105 and 9.195 were limited to moderate 
disarray and conspicuous individual hepatocyte necrosis 
with minimal lobular and portal inflammation. Exam-
ples of the histopathologic findings in recurrent HB are 
illustrated in Figures 2 and 3. Serum and tissue speci-
mens from all the patients obtained at the time of graft 
dysfunction secondary to HB demonstrated reoccur-
rence of detectable levels of viral antigens (see Tables 
3 and 4). 
The earliest histologic evidence of recurrent HB in-
fection was the presence of HBcAg in LB 8.29B in the 
cytoplasm of two or three hepatocytes and in one 
hepatocellular nucleus. Graft pathology, however, was 
not seen in this patient until 60 days later (LB 8.89B). 
Episodes of recurre'nt HB were treated with increased 
immunosuppression in Patients 1 and 2, because the 
initial pathologic changes were interpreted as rejection. 
At that time, immunoperoxidase staining was not done, 
nor were serologic studies taken into account. Both pa-
tients died of sepsis, which mayor may not have been 
related to HB. Immunosuppression therapy in the re-
maining patients was either reduced or unchanged af-
ter the diagnosis of HB, which resulted in self-limited 
resolution of acute graft dysfunction (Patients 3 and 
9) without viral clearing, maintenance of low·grade 
chronic disease activity (Patients 4 and 7), or acute ful-
minant HB requiring retransplantation (Patient 8A) 
Interestingly, in follow-up specimens from Patients 
2 and 9 (AU 2.450 and LB 9.223) there were minimal 
pathologic changes but marked expression of tissue viral 
antigens. 
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Figure 2A- Patient 2, LB 2.295 demonstrating marked lobular disarray, hepatocellular ballooning and extension of the inflammation into the lobule. (H&E, 
x 125) B- Higher-power magnification of the above section showing extension of the infiltrate into the lobule surrounding ballooned hepatocytes and 
intact bile ductule (arrow). (H&E, x315) C-AU 2.450. Note the lack of inflammation and of lobular changes. However, there is portal fibrosis with early 
bridging between the portal tracts and intact bile ductules (arfC1Nhead). (H&E, x 125) 0-Higher-power magnification of C demonstrating findings identi-
caito those outlined in C and expression of the HBcAg in many hepatocellular nuclei (srrow) as described by Gudat." (HBcAg immunoperoxidase with 
hematoxylin counterstain, x315) 
Discussion 
Though the histologic appearance of HBV hepatitis 
may be varied, the usual picture in the acute stage is 
one of lobular disarray, hepatocyte ballooning, and fo-
cal necrosis, accompanied by a Iymphohistiocytic lobu-
lar and portal tract infiltrate. 5 Focal inflammatory bile 
ductular and vascular endothelial infiltration and dam-
age may be present but usually are not prominent fea-
tures of the condition.5.Io,1I 
Portal inflammation is the hallmark of chronic hep-
atitis B. In spite of the location of the inflammatory 
infiltrate in CAHB, associated destruction of the por-
tal tract structures is usually not prominent. Instead, 
the presence of inflammatory cells with destruction of 
hepatocytes at the edge of the limiting plate is the rele-
vant feature. Furthermore, a histologic picture of loss 
of ductules, similar to that seen in primary biliary cir-
rhosis or the end stages of a rejected Iiver,1.12 has not 
been reported as a consequence of type B viral hepatitis5 
and was not seen in any of the cirrhotic primary resec-
tion specimens in this study. 
The histopathologic observations in HBV disease can 
be related to what is known about the virus. Specifically, 
the HBV is an enveloped partially doubled stranded 
DNA virus with a rather selective tissue tropism for he-
patocytes which has been linked to the presence of poly-
albumin receptors on the hepatocyte. 13 The mechanisms 
involved in the production of clinically important he-
patic disease by this virus are not well understood. Most 
studies agree that the HBV is not cytopathic. lJ-16 like-
wise, most of the circumstantial evidence collected from 
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Figure JA- Patient 8, LB 8.22M showing 
marked lobular Inflammation, disarray, and 
hepatocellular necrosis. (H&E, x 200) 
8 - Higher-power magnification of A show-
ing lobular inflammation with expression of 
HBcAg in the nudeus (arro.v) and cytoplasm 
(8rrCINhead) of the hepatocytes. (Immune-
peroxidase staining for HBcAg, x500) 
patient studies suggests that cell-mediated immune 
mechanisms are primarily responsible for the cell lysis 
and the viral clearing that occur during infection. 13-18 
Based on the present understanding of HBV disease, 
the hepatocyte appears to be the primary target of vi-
rus infection and therefore the focus of subsequent 
cellular-mediated cytolysis. Thus, the immune status of 
the host plays an important role in the type and spec-
trum of liver disease produced as a consequence of the 
viral infection. 
The histopathologic findings in the biopsy specimens 
obtained from the patients in this study who were di-
agnosed as having active HB virus infection as the pri-
mary pathologic process responsible for their graft dys-
function are consistent with the above concepts. The 
presence of lobular disarray with hepatocellular bal-
looning and individual cell necrosis in addition to a por-
tal and/or lobular inflammatory infiltrate of variable 
intensity without prominent vascular or bile ductular 
damage reflect the reappearance of HBeAg in the se-
rum and HBcAg in hepatocellular nuclei (markers of 
active viral replication). 
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Table 4 - Sequential Serologic Studies 
--------~--------~------------------------------------------------------------------
R.H. (2112182)" Pre-Tx 2124/82 
HBsAg Pes 162.02 Pos 29.01 
Anti HBs Neg Pos 4.02t 
Anti HBc Pos Pos 
HBeAg Neg Neg 
Anti HBe Pes Pos 
Anti-Delta Pos NO 
2 J.S (7123/81) Pre-Tx 8/24/81 
HBsAg Pos 130.8 Negt 
Anti HBs Neg Pos 23.«t 
Anti HBc Pos Pos 
HBeAg Pos 3.27 NO 
Anti HBe Neg Neg 
Anti·Delta Neg NO 
3 P.W.C. (12123/83) Pre-Tx 5110184 
HBsAG Pos 226.67 Negt 
Anti HBs Neg Pos 182.11 t 
Anti HBc Pos Pos 
HBeAg Pos NO 
Anti HBe Neg NO 
Anti·Delta Neg NO 
4 M.V.D. (2120/82) Pre-TJ( 312J82 
HBsAg Pos 183.37 Negt 
Anti HBs Neg Pos 3.94t 
Anti HBc Pos Pos 
HBeAg Pes 11.47 NO 
Anti HBe Neg NO 
Anti-Delta Neg NO 
5 J.L (11128184) Pre-TJ( 1213184 
HBsAg Pos 185.88 Pos 212.39 
Anti HBs Pos 3.19 Pos 75.88t 
Anti HBc Pos Pos 
HBeAg Neg Neg 
Anti HBe Neg Post 
Anti·Delta Neg NO 
6 O.A. (5126/84) Pre-TJ( 614/84 
HBsAG Pes 235.82 Pes 11.20 
Anti HBs Neg Pos 12.76 
Anti HBc Pas Pes 
HBeAg Neg Neg 
Anti HBe Pas Pos 
Anti·Delta Pos Pos 
7 AC. (11115/84) Pre-Tx 11123184 
HBsAg Pas 209.29 Pes 228.73 
Anti HBs Neg Neg 
Anti HBc Pas Pos 
HBeAg Pos Negt 
Anti HBe Neg Post 
Anti·Delta Neg NO 
8 O.T. (5111/85) Pre-TJ( 6119/85 
HBsAg Pas 253.01 Neg 
Anti HBs Neg Pos 248.06 
Anti HBc Pos Pos 
HBeAg Pos 3.52 NO 
Anti HBe Pos NO 
Anti·Delta Neg NO 
9 A.C. (5/30185) Pre-TJ( 6128185 
HBsAg Pas 171.14 Negt 
Anti HBs Neg Pos 
Anti HBc Pas Pos 
HBeAg Neg NO 
Anti HB Pas NO 
Anti·Delta Pas NO 
, Patilmt and date of transplantation. 
t Denotes change from previous determination. 
NO, not done. 
3/30182 
Pes 12.27 
'Neg 
Pos 
"'e" Pos 
NO 
4,'2182 
'f>os 167.8 
Neg 
Pos 
Pos 
Neg 
Neg 
&.8184 
Pos 182.11t 
Negt 
Pos 
Pos 7.96t 
Neg 
Neg 
31B182 
Neg 
Neg 
Pos 
NO 
Neg 
NO 
117185 
Negt 
Pas 357.16 
Pos 
NO 
NO 
NO 
6113184 
Negt 
Pas 118,01 
Pos 
NO 
NO 
NO 
3118/85 
Pas 125.68 
Neg 
Pas 
Pos 14.OSt 
Negt 
Neg 
12120/85 
Pos 143.67t 
Negt 
Pos 
Pos 16.30 
Neg 
Neg 
1116186 
Pos 118.61 t 
Neg 
Pos 
Neg 
Pes 
Pos 
6/21/82 
Pes 101.63 
Neg 
Pos 
Pos 23.57t 
Negt 
Pos 
9123182 
Pos 128.89 
Neg 
Pos 
Pos 31.47 
Neg 
NO 
8/17/84 
Pos 222.72 
Pos 11.SSt 
Pos 
Pos 8.OS 
Neg 
NO 
3118182 
Pos 3.24t 
Neg 
Pos 
Negt 
Neg 
Neg 
1/8/86 
Pos 190.51 
Neg 
Pos 
Pos 26.57 
Neg 
Neg 
2111/86 
Pos 179.35 
Neg 
Pos 
Neg 
Pos 
NO 
6/28/82 
Pos 203.62 
Neg 
Pos 
Post 
Neg 
NO 
215186 
Pas 156.80 
Pos 2.8 t 
Pes 
Pas 5.41 
Neg 
Neg 
3113186 
Pas In.41 
Negt 
Pos 
Pos 22.81 
Neg 
Neg 
'86 
In.41 
22.81 
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Immunohistochemical staining used to detect the 
presence of viral antigens within the liver tissue, while 
extremely helpful, may not be essential, 19 because ac-
tive HBV disease may be seen in the absence of detect-
able HB surface and core antigen expression in tissue. 
In contrast to the situation occurring in active HBV 
infection, the histologic appearance of liver rejection 
in patients on immunosuppressive therapy suggests that 
constituents of the portal tract are the preferential tar-
gets of immune destruction occurring as part of the 
rejection process. 1.2.12.20-23 These targets include portal 
tract connective tissue dendritic, venular endothelial, 
and biliary ductular epithelial ceIls, all of which may 
be related to the localization and expression of major 
histocompatibility complex (MHC) antigens2o.24.15 and to 
the functional anatomy of the liver. Though focal 
periportal and pericentral vein hepatocyte damage can 
be seen as a part of rejection, prominent extension of 
the lymphohistiocytic infiltrate into the hepatic lobule 
with ballooning, disarray, and marked individual he-
patocyte necrosis has not been a prominent feature of 
rejection in immunosuppressed patients in this or sever-
al other reported series of liver aliografts.I.l·21-2J The 
findings in biopsy specimens from patients during epi-
sodes of acute rejection in this study are consistent with 
these concepts and are more specific for rejection. Also, 
in failed liver allografts removed secondary to long-
standing rejection, it is not uncommon to find a near 
total absence of bile ductules and advanced portal fibro-
sis but with relative preservation of the hepatocytes and 
only a modest portal inflammatory infiItrate. ' ·12 
The validity of the argument that separation of graft 
dysfunction secondary to recurrent hepatitis B from 
acute cellular rejection is possible was confirmed by the 
events which followed each respective diagnosis. Graft 
dysfunction secondary to rejection responded clinically 
and biochemically to increased immunosuppression. 
Graft dysfunction secondary to hepatitis B resulted in 
self-limited resolution of acute dysfunction, main-
tenance of chronic disease activity, or fulminant fail-
ure, without alteration in immunosuppressive therapy. 
The syndrome of viral HB, therefore, is not dissimilar 
to that seen in non-liver allograft patients. However, 
no instance of viral antigen clearing was seen after recur-
rent infection in the posttransplant period despite ap-
parent self-limited dysfunction in some cases. 
Other interesting observations made during the re-
view of these cases include the following: 
1. In all patients transplanted with HBsAg-positive 
CAH, whether HBeAg or anti-delta agent positive or 
not, recurrent infection developed after more than 3 
months. The exception to this statement is the patient 
whose original disease was fulminant hepatic necrosis 
secondary to acute HB. He has apparently cleared the 
virus and is now immune to infection. 
2. Recurrent active HBV hepatitis (disease) was not 
thought to be responsible for allograft dysfunction at 
time periods earlier than 2 months after transplanta-
tion, despite an earlier serologic reappearance of HBsAg 
in the serum. 
3. Early posttransplant graft dysfunction occurring 
at any time less than 2 months after OLTx, was likely 
to be due to allograft rejection rather than active HB. 
It has been suggested that HB is a "mild disease" in 
immunocompromised hosts. '6 However, this study 
shows that at least in some patients, although they are 
immunosuppressed, HB does appear to cause progres-
sive and severe liver damage, as evidenced by the in-
crease in liver enzymes coincident with the reappear-
ance of serum and tissue viral antigens and the 
histologic appearance of recurrent CAH and cirrhosis. 
Similar observations have been made by Parfrey's 
group21 in renal transplant recipients who had chronic 
active HB. 
The clinical, serologic, and pathologic findings in this 
group of patients are quite similar to those reported 
by Corman et al6 in the previously well-documented case 
of recurrent HB in a liver allograft patient. Like that 
earlier case report, this report also emphasizes the 
similarity between recurrent hepatitis in liver allograft 
patients and that seen in posttranfusion HB, the pres-
ence of liver graft damage albeit different from the origi-
nal disease due to the B virus even though the patient 
is immunosuppressed and the histopathologic findings 
of a preferential lobular or hepatocellular insult. 
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